% CD19+ Lymphs

Elevated levels of "% CD19+ Lymphs" in a T + B-Lymphocyte Differential panel typically indicate an increased proportion of B cells in the blood. This can be associated with various conditions, including autoimmune diseases, where the immune system mistakenly targets healthy cells, or in certain types of leukemia, where there is an abnormal proliferation of B cells. Elevated B cell levels can also occur in response to infections as the body ramps up its immune response. However, interpreting these levels should be done carefully in the context of the overall clinical scenario and other diagnostic findings.

Decreased levels of "% CD19+ Lymphs" in a T + B-Lymphocyte Differential panel suggest a reduced proportion of B cells in the blood. This can be significant as B cells are crucial for the body's humoral immune response, primarily responsible for antibody production. Low B cell levels can occur in certain immunodeficiency disorders, where the immune system's ability to fight infections is compromised. It might also be seen in individuals receiving immunosuppressive therapy or in certain genetic conditions affecting B cell development and function. As with elevated levels, interpreting these low levels requires considering the overall health context and other medical findings.

The biomarker "% CD19+ Lymphs" in a T + B-Lymphocyte Differential panel from Labcorp quantifies the percentage of lymphocytes in the blood that are B cells, identified by the presence of the CD19 protein on their surface. CD19 is a critical component of the B cell receptor complex and plays a vital role in the development and function of B cells. B cells are essential for the adaptive immune response, primarily responsible for antibody production.